{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:02:53Z","timestamp":1784808173692,"version":"3.55.0"},"reference-count":24,"publisher":"Jaypee Brothers Medical Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.59556\/japi.74.1548","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:12:29Z","timestamp":1781601149000},"page":"56-65","source":"Crossref","is-referenced-by-count":0,"title":["Imeglimin in Indian Adults with Type 2 Diabetes: A Prospective Multicenter Real-world Cohort Study of Prescription Patterns, Glycemic Change, and Safety"],"prefix":"10.59556","volume":"74","author":[{"given":"Bharat","family":"Saboo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambo Samrat","family":"Samajdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant Kumar","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket V","family":"Inamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajyoti","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhashree","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutul","family":"Gokalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Kiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagendra Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Pamnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hridish Narayan","family":"Chakravarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh Kumar","family":"Agrawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Tamhankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(1):","key":"key20260723111953_B1","doi-asserted-by":"crossref","first-page":"7\u2013","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF Diabetes Atlas 11th edition 2025: Global prevalence and projections for 2050.","volume":"41","author":"Duncan","year":"2025;","journal-title":"Nephrol Dial Transplant"},{"issue":"(7):","key":"key20260723111953_B2","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: The ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260723111953_B3","doi-asserted-by":"crossref","first-page":"2042018820980225.","DOI":"10.1177\/2042018820980225","article-title":"Should metformin remain the first-line therapy for treatment of type 2 diabetes?","volume":"12:","author":"Baker","year":"2021;","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"(Suppl 1):","key":"key20260723111953_B4","doi-asserted-by":"crossref","first-page":"S111\u2013","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: Standards of care in diabetes-2024.","volume":"47","author":"American Diabetes Association Professional Practice Committee.","year":"2024;","journal-title":"Diabetes Care"},{"key":"key20260723111953_B5","doi-asserted-by":"crossref","first-page":"116755.","DOI":"10.1016\/j.biopha.2024.116755","article-title":"Exploring new mechanisms of imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.","volume":"175:","author":"Li","year":"2024;","journal-title":"Biomed Pharmacother"},{"key":"key20260723111953_B6","unstructured":"Kumar S, Shukla R, Smajhdar S, et al. (2025). Mitochondrial dysfunction in type 2 diabetes mellitus: Imeglimin as a novel therapeutic approach. [online] Available from: https:\/\/ajd.ijcp.in\/Pages\/Post_Detail.aspx?wid=102 [Last accessed March, 2026]."},{"issue":"(1):","key":"key20260723111953_B7","doi-asserted-by":"crossref","first-page":"6178.","DOI":"10.1038\/s41598-024-56769-w","article-title":"Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic \u03b2-cells from db\/db mice.","volume":"14","author":"Aoyagi","year":"2024;","journal-title":"Sci Rep"},{"issue":"(6):","key":"key20260723111953_B8","doi-asserted-by":"crossref","first-page":"e15\u2013","DOI":"10.59556\/japi.73.0938","article-title":"Imeglimin in type 2 diabetes mellitus: Expert opinions and consensus in Indian context.","volume":"73","author":"Seshadri","year":"2025;","journal-title":"J Assoc Physicians India"},{"issue":"(1):","key":"key20260723111953_B9","doi-asserted-by":"crossref","first-page":"357.","DOI":"10.1186\/s13098-025-01922-2","article-title":"Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: An umbrella review and systematic review, meta-regression and meta-analysis.","volume":"17","author":"Song","year":"2025;","journal-title":"Diabetol Metab Syndr"},{"issue":"(3):","key":"key20260723111953_B10","doi-asserted-by":"crossref","first-page":"664\u2013","DOI":"10.1111\/dom.14277","article-title":"Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes.","volume":"23","author":"Hallakou-Bozec","year":"2021;","journal-title":"Diabetes Obes Metab"},{"issue":"(8):","key":"key20260723111953_B11","first-page":"e66322.","article-title":"Imeglimin for type 2 diabetes mellitus: Its efficacy and insight into the potential benefit for renal and liver function.","volume":"16","author":"Uto","year":"2024;","journal-title":"Cureus"},{"issue":"(4):","key":"key20260723111953_B12","doi-asserted-by":"crossref","first-page":"952\u2013","DOI":"10.2337\/dc20-0763","article-title":"Efficacy and safety of imeglimin monotherapy vs placebo in Japanese patients with type 2 diabetes (TIMES 1): A double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial.","volume":"44","author":"Dubourg","year":"2021;","journal-title":"Diabetes Care"},{"issue":"(3):","key":"key20260723111953_B13","doi-asserted-by":"crossref","first-page":"154\u2013","DOI":"10.5603\/cd.104962","article-title":"Safety and efficacy of imeglimin in type 2 diabetes individuals with metformin intolerance: A case-control study.","volume":"14","author":"Agrawal","year":"2025;","journal-title":"Clin Diabetol"},{"issue":"(1):","key":"key20260723111953_B14","doi-asserted-by":"crossref","first-page":"e14\u2013","DOI":"10.59556\/japi.73.0795","article-title":"Two concerns and a single solution in managing type 2 diabetes: A narrative review on imeglimin.","volume":"73","author":"Samajdar","year":"2025;","journal-title":"J Assoc Physicians India"},{"key":"key20260723111953_B15","doi-asserted-by":"crossref","first-page":"1639046.","DOI":"10.3389\/fendo.2025.1639046","article-title":"Imeglimin-based therapies improve glycemic control and reduce mitochondrial stress in type 2 diabetes: a prospective cohort study.","volume":"16:","author":"Satheesan","year":"2025;","journal-title":"Front Endocrinol"},{"issue":"(11):","key":"key20260723111953_B16","doi-asserted-by":"crossref","first-page":"1068\u2013","DOI":"10.1016\/j.jdiacomp.2018.08.001","article-title":"Body fat, metabolic syndrome and hyperglycemia in South Asians.","volume":"32","author":"Misra","year":"2018;","journal-title":"J Diabetes Complications"},{"issue":"(1):","key":"key20260723111953_B17","doi-asserted-by":"crossref","first-page":"262.","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: Pathogenesis, prevention and therapy.","volume":"9","author":"Lu","year":"2024;","journal-title":"Signal Transduct Target Ther"},{"issue":"(11):","key":"key20260723111953_B18","doi-asserted-by":"crossref","first-page":"1246\u2013","DOI":"10.1111\/jdi.14070","article-title":"Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","volume":"14","author":"Hagi","year":"2023;","journal-title":"J Diabetes Investig"},{"issue":"(2):","key":"key20260723111953_B19","doi-asserted-by":"crossref","first-page":"102710.","DOI":"10.1016\/j.dsx.2023.102710","article-title":"Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"17","author":"Singh","year":"2023;","journal-title":"Diabetes Metab Syndr"},{"issue":"(6):","key":"key20260723111953_B20","doi-asserted-by":"crossref","first-page":"102323.","DOI":"10.1016\/j.dsx.2021.102323","article-title":"Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized .","volume":"15","author":"Abdelhaleem","year":"2021;","journal-title":"clinical trialsDiabetes Metab Syndr"},{"issue":"(4):","key":"key20260723111953_B21","doi-asserted-by":"crossref","first-page":"609\u2013","DOI":"10.1111\/dom.14613","article-title":"Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.","volume":"24","author":"Dubourg","year":"2022;","journal-title":"Diabetes Obes Metab"},{"issue":"(4):","key":"key20260723111953_B22","doi-asserted-by":"crossref","first-page":"645\u2013","DOI":"10.1007\/s13300-025-01693-z","article-title":"A multicenter, retrospective study to evaluate the effectiveness and safety of imeglimin in patients with type 2 diabetes mellitus in a real-world clinical setting (INDI-TIMES study).","volume":"16","author":"Shaikh","year":"2025;","journal-title":"Diabetes Ther"},{"issue":"(3):","key":"key20260723111953_B23","doi-asserted-by":"crossref","first-page":"565\u2013","DOI":"10.2337\/dc12-0453","article-title":"The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.","volume":"36","author":"Fouqueray","year":"2013;","journal-title":"Diabetes Care"},{"issue":"(4):","key":"key20260723111953_B24","doi-asserted-by":"crossref","first-page":"923\u2013","DOI":"10.1007\/s13410-025-01453-6","article-title":"Comparing the safety and effectiveness of imeglimin and vildagliptin as add-on therapies in type 2 diabetes patients: A record-based study.","volume":"45","author":"Samajdar","year":"2025;","journal-title":"Int J Diabetes Dev Ctries"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:20:00Z","timestamp":1784805600000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-6-56"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.59556\/japi.74.1548"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1548","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}